MARKET

BCAB

BCAB

Bioatla, Inc.
NASDAQ
0.2106
+0.0205
+10.78%
After Hours: 0.1650 -0.0456 -21.65% 19:56 02/06 EST
OPEN
0.1933
PREV CLOSE
0.1901
HIGH
0.2238
LOW
0.1925
VOLUME
3.00M
TURNOVER
--
52 WEEK HIGH
1.430
52 WEEK LOW
0.1400
MARKET CAP
12.43M
P/E (TTM)
-0.1829
1D
5D
1M
3M
1Y
5Y
1D
BioAtla Faces Nasdaq Trading Suspension and Potential Delisting
TipRanks · 1d ago
BioAtla Faces Nasdaq Delisting Over Listing Rule Violations
Reuters · 1d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/6/26
TipRanks · 1d ago
VOO vs. VTI vs. VTWO: Which Vanguard ETF Offers the Best Upside in 2026?
TipRanks · 1d ago
Vanguard Total Stock Market ETF (VTI) Daily Update—2/5/26
TipRanks · 2d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/4/26
TipRanks · 3d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/3/26
TipRanks · 4d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 5d ago
More
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Webull offers Bioatla Inc stock information, including NASDAQ: BCAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCAB stock methods without spending real money on the virtual paper trading platform.